AstraZeneca: Truqap Plus Fulvestrant Approved in the US for Patients With Advanced HR-Positive Breast Cancer
November 18, 2023
November 18, 2023
WILMINGTON, Delaware, Nov. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's TRUQAP (capivasertib) in combination with fulvestrant has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the . . .
AstraZeneca's TRUQAP (capivasertib) in combination with fulvestrant has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the . . .